Advertisement

Topics

FDA approves Praluent to treat certain patients with high cholesterol

10:15 EDT 24 Jul 2015 | FDA

The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.

Original Article: FDA approves Praluent to treat certain patients with high cholesterol

NEXT ARTICLE

More From BioPortfolio on "FDA approves Praluent to treat certain patients with high cholesterol"

Advertisement
Quick Search
Advertisement
Advertisement